Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses H101.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Liu Zi

Criteria

Inclusion Criteria:

• Written informed consent obtained.

• Age ≥ 18 years at the time of study entry.

• Histological or Cytologically diagnosed gynecological malignancies.

• Failure to prior standard treatment (surgery, chemotherapy, radiotherapy);

• Refractory/recurrence/metastasis gynecological cancer

• At least one measurable lesion according to the RECIST1.1.

• Cooperative Oncology Group-Status (ECOG Status) 0-3.

• The last treatment should be over 2 weeks.

Exclusion Criteria:

• History or evidence of active autoimmune disease that requires systemic treatment.

• Participated in other anti-tumor clinical trials within 4 weeks.

• Patients who have a contraindication to similar drugs.

• That failure to follow up regularly.